Legend Holdings reinvested in life sciences R&D services provider Pharmaron, co-leading a $280m round closed four years after a $40m series C.
US-based life science research provider Pharmaron raised $280m on Friday from a consortium co-led by Legend Capital, conglomerate Legend Holding’s corporate venturing arm, and private equity fund Citic M&A Fund.
Founded in 2003, Pharmaron provides research and development services for the life sciences industry. It has more than 3,000 employees spread across China, where Legend Capital and Citic are based, and the US and serves companies in North America, Europe, Japan and China.
Pharmaron will invest the money in enhancing…
